Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Investigation of Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer Patients Managed With Primary (Chemo) Radiation

NCT05800574 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT05800574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05800574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Investigation of Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer Patients Managed With Primary (Chemo) Radiation
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
March 14, 2023
Completion date
September 23, 2027
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oropharynx cancer